激肽释放酶结合蛋白与蛋白C抑制剂的可能同一性。

Possible identity of kallikrein binding protein with protein C inhibitor.

作者信息

Ecke S, Geiger M, Resch I, Jerabek I, Maier M, Binder B R

机构信息

Laboratory for Clinical Experimental Physiology, University of Vienna, Austria.

出版信息

Agents Actions Suppl. 1992;38 ( Pt 1):182-9. doi: 10.1007/978-3-0348-7321-5_24.

DOI:10.1007/978-3-0348-7321-5_24

PMID:1334618

Abstract

Protein C inhibitor (PCI) inhibits tissue kallikrein by forming stable 1:1 complexes (k1 = 2.3 x 10(4)M-1s-1). Heparin inhibits the tissue kallikrein/PCI-interaction and complex formation of 125I-tissue kallikrein in serum. 125I-tissue kallikrein complexes formed in plasma can be immunoprecipitated with monoclonal anti-PCI IgG suggesting that PCI might be identical to the kallikrein binding protein described previously (J. Chao et al. 1986, Biochem. J. 239, 325-331).

摘要

蛋白C抑制剂（PCI）通过形成稳定的1:1复合物（k1 = 2.3 x 10(4)M-1s-1）来抑制组织激肽释放酶。肝素抑制组织激肽释放酶/PCI的相互作用以及血清中125I-组织激肽释放酶的复合物形成。血浆中形成的125I-组织激肽释放酶复合物可用单克隆抗PCI IgG进行免疫沉淀，这表明PCI可能与先前描述的激肽释放酶结合蛋白相同（J. Chao等人，1986年，《生物化学杂志》239卷，325 - 331页）。